MeiraGTx Holdings plc (MGTX)

Market: NASD | Currency: USD

Address: 450 East 29th Street

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. Show more

📈 MeiraGTx Holdings plc Historical Chart

📊 Statistics

Analyst 1 Year Price Target: $27.33
Upside/Downside from Analyst Target: 264.93%
Broker Call: 12
Dividend Minimum 3 Year Yield: 0.00%
EPS Growth Range (1Y): <0%
Net Income Growth Range (1Y): <0%
Revenue Growth Range (1Y): 200-500%
Upcoming Earnings Date: 2025-11-12
EPS Estimate: -0.54

💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for MeiraGTx Holdings plc

Date	Reported EPS
2025-11-12 (estimated upcoming)	-
2025-08-14	-0.48
2025-05-13	-0.51
2025-03-13	-0.5
2024-11-13	-0.55
2024-08-12	-0.76
2024-05-09	-0.77
2024-03-14	-0.54
2023-11-14	-0.74
2023-08-10	-0.53
2023-05-11	-0.62
2023-03-14	-0.58
2022-11-10	-0.83
2022-08-11	-0.76
2022-05-12	-0.7
2022-03-10	-0.22
2021-11-10	-0.59
2021-08-11	-0.46
2021-05-11	-0.54
2021-03-11	-0.25
2020-11-05	-0.17
2020-08-06	-0.69
2020-05-07	-0.43
2020-03-11	-0.12
2019-11-07	-0.3

📰 Related News & Research

No related articles found for "meiragtx holdings".